What is the Purpose of this Study?
The purpose of this study is to evaluate an investigational drug called BA3071 as a potential treatment in combination with another drug, nivolumab, in patients with advanced solid tumor cancers. Nivolumab is an immunotherapy approved for melanoma treatment and other cancers. This study will evaluate the safety of different doses of BA3071, also an immunotherapy that targets CTLA-4 immune checkpoint, when given in combination with nivolumab and determine the effects it has on patients and their cancer. Additionally, researchers will choose the dose amount to be used in future studies and identify the highest dose of the drug to be used in this study that patients can receive without having severe symptoms. The study also aims to understand how the body absorbs and processes various doses of BA3071 by measuring the amount of the study drug in the blood before, during and after receiving BA3071 in combination with nivolumab (pharmacokinetics).
Eligibility
- * Patients must have measurable disease.
- * Age ≥ 18 years
- * CLTA-4 blocking-antibody naïve
- * Adequate renal function
Where can I participate?
- CS Cancer at Cedars-Sinai Medical Center : Saba Mukarram
- CS Cancer at The Angeles Clinic and Research Institute : Saba Mukarram
More about this Clinical Trial
What is the full name of this clinical trial?
BA3071-001: A Phase 1/2 Study of BA3071 in Patients with Solid Tumors